Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

100022

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Patient Choice Schemes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to promote patient choice.
	tabling member constituency	Stroud
	tabling member printed	Neil Carmichael
	uin	905559
	answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.</p><p> </p><p> </p><p> </p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/10/2014 16:00:56 answering member 4020 label Biography information for George Freeman
	tabling member	4104 label Biography information for Neil Carmichael

93556

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmaceutical Price Regulation Scheme
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions (a) he or (b) officials in his Department have had on reinvesting the industry rebate payments under the current Pharmaceutical Price Regulation Scheme into (i) healthcare services and (ii) medicines expenditure.
	tabling member constituency	Cambridge
	tabling member printed	Dr Julian Huppert
	uin	210807
	answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>The Pharmaceutical Price Regulation Scheme (PPRS) as agreed with the Association of the British Pharmaceutical Industry (ABPI) does not cover the onward financial flows of payments to the National Health Service which are subject to the Government accounting and budgeting rules in the normal way. In particular there was no agreement to hypothecate PPRS payments. The Department has subsequently had a number of discussions with the ABPI and NHS England about the onward financial flows.</p><p> </p><p> </p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the mandate and as such were included within commissioner allocations. The same is expected to apply in 2015-16. This means that the effect of the deal is felt across the NHS through the general funding allocations to clinical commissioning groups.</p><p> </p><p> </p><p> </p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the ABPI are discussing how best to improve access to and optimise patient outcomes from these medicines.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 22/10/2014 15:38:43 answering member 4020 label Biography information for George Freeman
	tabling member	3931 label Biography information for Dr Julian Huppert

93563

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Surgical Mesh Implants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will review his policy on polypropylene transvaginal mesh implants in response to recent court judgements in the US.
	tabling member constituency	Newcastle upon Tyne East
	tabling member printed	Mr Nicholas Brown
	uin	210655
	answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>A working group, chaired by NHS England and including patient representatives, clinical representatives, the Department and the Medicines and Healthcare Products Regulatory Agency, has been set up to understand and address the concerns which have been raised about transvaginal mesh implants.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 22/10/2014 15:19:50 answering member 4020 label Biography information for George Freeman
	tabling member	523 label Biography information for Mr Nicholas Brown

93566

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmaceutical Price Regulation Scheme
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the value is of the rebate payments made by industry under the Pharmaceutical Price Regulation Scheme to date; and what proportion of that rebate has been reinvested in (i) healthcare services and (ii) medicines expenditure.
	tabling member constituency	Cambridge
	tabling member printed	Dr Julian Huppert
	uin	210640
	answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014 and £76 million in respect of the second quarter. The Department will publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first two quarters PPRS payments were published in June and September 2014 respectively and can be found on the Government’s website at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information" target="_blank">https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information</a></p><p> </p><p> </p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/10/2014 16:15:30 answering member 4020 label Biography information for George Freeman
	tabling member	3931 label Biography information for Dr Julian Huppert

93568

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what funding his Department provides for businesses and organisations conducting research into the benefits of natural products in cancer therapy and treatment.
	tabling member constituency	Belfast North
	tabling member printed	Mr Nigel Dodds
	uin	210719
	answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>The Government has funding mechanisms in place for research and development relating to cancer treatments.</p><p> </p><p> </p><p> </p><p>The Department's National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including the use of natural products in cancer treatment. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>The NIHR is investing £16 million over five years (to 2017) in 14 Experimental Cancer Medicine Centres (ECMCs) across England with joint funding from Cancer Research UK. These centres bring together laboratory and clinical patient-based research to speed up the development of innovative cancer therapies and individualise patient treatment. Researchers at the Leicester ECMC are currently looking at whether curcumin – found in turmeric – can improve drug response in patients with advanced bowel cancer.</p><p> </p><p> </p><p> </p><p>The NIHR manages the Efficacy and Mechanism Evaluation programme, which bridges the gap between preclinical studies and evidence of clinical efficacy. The aim is to secure the progress of new technologies and interventions through their early clinical trials and onto larger, later clinical trials. The programme is funded by the Medical Research Council (MRC) and the NIHR and is not currently funding any studies of the use of natural products in cancer treatment.</p><p> </p><p> </p><p> </p><p>Other sources of funding include the Biomedical Catalyst, which is a funding programme jointly operated by the MRC and Innovate UK. The programme provides responsive and effective support for the best translational life science opportunities arising. Grants are available to UK academics and small and medium enterprises seeking to move their research more quickly from discovery to commercialisation.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 22/10/2014 15:10:04 answering member 4020 label Biography information for George Freeman
	tabling member	1388 label Biography information for Lord Dodds of Duncairn

93570

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the cost was of providing free prescriptions to people with diabetes in (a) England and (b) Havering in 2013-14.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	210702
	answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>Information is not available in the format requested</p><p> </p><p> </p><p> </p><p>Diabetes and Myxoedema are two of the specific conditions which entitle individuals to apply for a medical exemption certificate to provide them with exemption from prescription charges.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 210703 question first answered 22/10/2014 15:33:24 answering member 4020 label Biography information for George Freeman
	tabling member	1447 label Biography information for Andrew Rosindell

93571

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Thyroid Gland
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the cost was of providing free prescriptions to people with myxodema in (a) England and (b) Havering in 2013-14.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	210703
	answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>Information is not available in the format requested</p><p> </p><p> </p><p> </p><p>Diabetes and Myxoedema are two of the specific conditions which entitle individuals to apply for a medical exemption certificate to provide them with exemption from prescription charges.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 210702 question first answered 22/10/2014 15:33:24 answering member 4020 label Biography information for George Freeman
	tabling member	1447 label Biography information for Andrew Rosindell

93573

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund: Liverpool
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what proportion of the cancer drugs fund has been spent in Liverpool since its inception.
	tabling member constituency	Liverpool, Walton
	tabling member printed	Steve Rotheram
	uin	210689
	answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>Prior to April 2013, information on the Cancer Drugs Fund was administered through clinical panels based in each strategic health authority (SHA) and data on spend through the Fund in each city was not collected. Information on spend by the North West SHA and in England in 2010-11, 2011-12 and 2012-13 is shown in the following table:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Amount Spent (£000)</p><p>2010-11</p></td><td><p>Amount Spent (£000)<br> 2011-12</p></td><td><p>Amount Spent (£000)<br> 2012-13</p></td></tr><tr><td><p>North West SHA</p></td><td><p>7,400</p></td><td><p>10,015</p></td><td><p>29,272</p></td></tr><tr><td><p>England</p></td><td><p>38,254</p></td><td><p>108,327</p></td><td><p>175,334</p></td></tr></tbody></table><p> </p><p><em>Source</em>: Information provided to the Department by SHAs</p><p> </p><p> </p><p> </p><p>NHS England has had oversight of the Fund since April 2013 and does not collect information at city level. In 2013-14, £63,368,429 was spent through the Fund in the North of England region and total national expenditure in England, net of any central rebates, was £230,539,005. Figures for 2014-15 are not currently available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/10/2014 16:20:31 answering member 4020 label Biography information for George Freeman
	tabling member	4035 label Biography information for Steve Rotheram